Analyzing NKGen Biotech (NKGN) and Its Peers

NKGen Biotech (NYSE:NKGN) is one of 280 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it compare to its rivals? We will compare NKGen Biotech to similar companies based on the strength of its risk, analyst recommendations, valuation, earnings, profitability, dividends and institutional ownership.

Volatility and Risk

NKGen Biotech has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500. Comparatively, NKGen Biotech’s rivals have a beta of 1.08, indicating that their average stock price is 8% more volatile than the S&P 500.

Valuation & Earnings

This table compares NKGen Biotech and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
NKGen Biotech	$80,000.00	-$82.94 million	-0.08
NKGen Biotech Competitors	$556.01 million	-$34.22 million	-44.19

NKGen Biotech’s rivals have higher revenue and earnings than NKGen Biotech. NKGen Biotech is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares NKGen Biotech and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NKGen Biotech	N/A	N/A	-479.36%
NKGen Biotech Competitors	-5,115.55%	-171.71%	-42.81%

Analyst Ratings

This is a breakdown of current recommendations and price targets for NKGen Biotech and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NKGen Biotech	0	0	0	0	N/A
NKGen Biotech Competitors	1578	4710	12268	236	2.59

As a group, “Biological products, except diagnostic” companies have a potential upside of 58.72%. Given NKGen Biotech’s rivals higher probable upside, analysts plainly believe NKGen Biotech has less favorable growth aspects than its rivals.

Institutional & Insider Ownership

76.2% of NKGen Biotech shares are held by institutional investors. Comparatively, 50.4% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 20.0% of NKGen Biotech shares are held by company insiders. Comparatively, 16.4% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

About NKGen Biotech

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.